Abdominal Aortic Aneurysms - Pipeline Review, H1 2014

Abdominal Aortic Aneurysms - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Abdominal Aortic Aneurysms - Pipeline Review, H1 2014’, provides an overview of the Abdominal Aortic Aneurysms’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Abdominal Aortic Aneurysms, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Abdominal Aortic Aneurysms and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Abdominal Aortic Aneurysms
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Abdominal Aortic Aneurysms and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Abdominal Aortic Aneurysms products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Abdominal Aortic Aneurysms pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Abdominal Aortic Aneurysms
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Abdominal Aortic Aneurysms pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Abdominal Aortic Aneurysms Overview 6
Therapeutics Development 7
Pipeline Products for Abdominal Aortic Aneurysms - Overview 7
Pipeline Products for Abdominal Aortic Aneurysms - Comparative Analysis 8
Abdominal Aortic Aneurysms - Therapeutics under Development by Companies 9
Abdominal Aortic Aneurysms - Therapeutics under Investigation by Universities/Institutes 10
Abdominal Aortic Aneurysms - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Abdominal Aortic Aneurysms - Products under Development by Companies 13
Abdominal Aortic Aneurysms - Products under Investigation by Universities/Institutes 14
Abdominal Aortic Aneurysms - Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Novartis AG 16
Spherix Incorporated 17
Abdominal Aortic Aneurysms - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ticagrelor - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
canakinumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CRD-007 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
doxycycline - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(SPX-106 + D-tagatose) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
BSN-908 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Abdominal Aortic Aneurysms - Recent Pipeline Updates 40
Abdominal Aortic Aneurysms - Product Development Milestones 50
Featured News & Press Releases 50
Aug 13, 2012: Spherix's SPX106T Reduces Growth Rate Of Abdominal Aortic Aneurysms In Preclinical Studies 50
Oct 05, 2011: Cardoz Announces Successful Completion Of Patient Enrollment In AORTA Trial Investigating CRD007 In Patients With Abdominal Aortic Aneurysm 50
Jun 08, 2011: Cardoz Starts Phase II Dose-finding Trial For New Oral Drug Treatment For Abdominal Aortic Aneurysm 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Number of Products under Development for Abdominal Aortic Aneurysms, H1 2014 7
Number of Products under Development for Abdominal Aortic Aneurysms - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Abdominal Aortic Aneurysms - Pipeline by AstraZeneca PLC, H1 2014 15
Abdominal Aortic Aneurysms - Pipeline by Novartis AG, H1 2014 16
Abdominal Aortic Aneurysms - Pipeline by Spherix Incorporated, H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Assessment by Combination Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Abdominal Aortic Aneurysms Therapeutics - Recent Pipeline Updates, H1 2014 40

List of Figures
Number of Products under Development for Abdominal Aortic Aneurysms, H1 2014 7
Number of Products under Development for Abdominal Aortic Aneurysms - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27